Day Two
Thursday 18th April 2024
8:30 am Check In, Morning Coffee & Light Breakfast
9:30 am Chair’s Opening Remarks
Towards First-in-Human: Taking Compounds to the Clinic
9:45 am Development of a Topical Containing a Non-Coding Oligonucleotide
Synopsis
• Proof-of-concept study in canines with atopic dermatitis
• Cutaneous CD11b+ cells that inhibit Th1/2/9 responses and promote Tregs are recruited by a non-coding oligonucleotide
• Upregulation of immune-checkpoint proteins on cutaneous CD11b+ cells
10:15 am Pearls of Perfect Efficacy Data in Dermatology Clinical Trialsx
Synopsis
- Efficacy data in dermatology clinical trials (Hidradenitis Suppurativa and Psoriasis)
- Main concerns and ways to monitor
- Lessons learned
10:45 am Morning Break & Networking
Synopsis
Meet and connect with your peers in this dedicated networking session
Clinical Strategies in Dermatology: Clinical Progress & Novel Strategies Shaping Today’s Drug Development Landscape
11:45 am Rezpegaldesleukin, a Regulatory T-Cell Selective IL-2 Conjugate: Lessons Learned From Preclinical Design to Clinical Evaluation in Inflammatory Skin Diseases Including Atopic Dermatitis
Synopsis
• Use of the appropriate design elements and experimental models for generation and preclinical evaluation
• Using clinical development approaches to address target engagement and assess PK/PD principles
• Using clinical studies to identify the correlation between the MOA and the indication
12:15 pm Expanding the Role of the IL-17A & IL-17F inhibiting Nanobody® Sonelokimab Across Derm & Rheum Indications – Data from a Global Placebo- & Active Comparator-Controlled Phase 2 Study in Psoriatic Arthritis
Synopsis
- Explore the rapid achievement of high response levels in joints and skin across ACR and PASI thresholds, as well as composite measures such as MDA, shedding light on the dynamics of clinical response patterns
- Consistent safety results observed in the ARGO and previous sonelokimab trials, emphasising the absence of new safety signals and contributing additional insights into the safety profile of IL-17 inhibitors
- Investigate the broader impact of sonelokimab on patient-reported quality of life, and across psoriatic disease domains, examining the depth of response beyond the primary endpoint, and its significance in the context of improving the overall well-being of patients
12:45 pm Lunch Break
Synopsis
Take this chance to meet the expert speakers, connect with your peers and explore our exhibition booths
Navigating European Healthcare Infrastructure: Enabling Accuracy in Diagnosis & Expanding Access to Novel Therapeutics
1:45 pm Roundtable Discussion:Navigating & Re-Thinking Market Access Strategies in European Dermatology Drug Development
Synopsis
In the dynamic landscape of dermatology drug development, securing successful market
access in Europe is a pivotal milestone for biopharma innovators. This interactive discussion brings together large pharma, biotech, clinician and market access strategists to delve into the crucial considerations for planning ahead in this complex journey in a more informed manner compared to today.
Use this opportunity to discuss the intricacies of European regulatory, HTA criteria and payer engagement strategies to optimise development timelines, approval processes, craft reimbursement models and ultimately navigate diverse markets to maximise patient access to novel therapies.
Join us for a collaborative exploration of strategies and insights that will empower
your end-to-end dermatology drug development journey in the European market!
2:45 pm Adopting Novel Strategies for Chronic Skin Conditions in Clinical Practice
Synopsis
• Given the latest developments and approvals of new treatments in dermatology, are these therapies proving effective and safe when applied in real-world clinical scenarios?
• Are the newly available treatments in dermatology leading to sustained improvements in patients’ quality of life over time?
• How can learnings from clinical practice inform future research and the evolution towards a personalised medicine approach in treating dermatologic conditions?